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Abstract
G protein-coupled receptors (GPCRs) activate mitogen-activated protein kinases through a number of distinct pathways in
cells. Increasing evidence has suggested that endosomal signaling has an important role in receptor signal transduction.
Here we investigated the involvement of endocytosis in a1A-adrenergic receptor (a1A-AR)-induced activation of extracellular
signal-regulated kinase 1/2 (ERK1/2). Agonist-mediated endocytic traffic of a1A-AR was assessed by real-time imaging of
living, stably transfected human embryonic kidney 293A cells (HEK-293A). a1A-AR was internalized dynamically in cells with
agonist stimulation, and actin filaments regulated the initial trafficking of a1A-AR. a1A-AR-induced activation of ERK1/2 but
not p38 MAPK was sensitive to disruption of endocytosis, as demonstrated by 4uC chilling, dynamin mutation and treatment
with cytochalasin D (actin depolymerizing agent). Activation of protein kinase C (PKC) and C-Raf by a1A-AR was not affected
by 4uC chilling or cytochalasin D treatment. U73122 (a phospholipase C [PLC] inhibitor) and Ro 31–8220 (a PKC inhibitor)
inhibited a1B-AR- but not a1A-AR-induced ERK1/2 activation. These data suggest that the endocytic pathway is involved in
a1A-AR-induced ERK1/2 activation, which is independent of Gq/PLC/PKC signaling.
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Introduction
a1A-Adrenergic receptor (a1A-AR) is one of 3 members of the
a1-AR subfamily (a1A, a1B, and a1D) of G protein-coupled
receptors (GPCRs) [1–3]. a1A-AR plays a key role in physiological
effects such as contraction of vascular and cardiac muscle,
contraction of the spleen, liver glycogenesis, or melatonin secretion
in the pineal gland [2–5]. Mice with cardiac-restricted overex-
pression of the wild-type a1B-AR that were treated with a1-AR
agonist (phenylephrine [PE]) exhibited poor survival, markedly
exaggerated cardiac hypertrophy, myocardial fibrosis, and sup-
pressed left ventricular function [6]. In contrast, animals with a1A-
AR overexpression showed improved survival and even abrogated
cardiac remodeling in response to thoracic aorta constriction-
induced pressure overload or myocardial infarction [7,8]. The
activation of extracellular signal-regulated kinase (ERK), a
regulator of myocyte survival, is critical in mediating a1-AR
survival signaling in cardiac myocytes [9–11]. Recent studies of
selective inactivation of a1-ARs indicate that the activation of
ERK1/2 induced by a1A-AR is critical for cardiomyocyte survival.
Reconstitution of a1A-AR but not a1B-AR induced ERK1/2
activation and rescued a1ABKO myocytes from cell death
induced by norepinephrine, doxorubicin, and H2O2 [12]. The
observation that a1A-AR specifically restored ERK1/2 activation
in a1ABKO myocytes suggests that a1A-AR and a1B-AR activate
ERK1/2 through differential mechanisms. However, studies to
date have not consistently identified major differences in
immediate signaling responses initiated by a1A-AR and a1B-AR.
a1A-AR is regulated by many mechanisms, including phosphor-
ylation, protein-protein interaction, protein traffic, and transcrip-
tion [13]. After stimulation by their ligands, a1-ARs activate
intracellular effectors, including phospholipase C b (PLCb),
inositol trisphosphate, protein kinase C (PKC), mitogen-activated
protein kinase (MAPK) and calcium signals, often through a
heterotrimeric G protein-dependent manner [14,15]. An a1A-AR
variant, which was unable to couple to Gq, could also induce
calcium influx when coactivated by b2-AR [16]. Thus, a1A-AR,
even though uncoupled from Gq, may remain competent for
induction of signaling events through yet unknown pathways.
Increasing evidence has shown the existence of receptor
signaling from the endocytic process. For instance, activation of
ERK1/2 via epidermal growth factor receptor (EGFR) and b2-AR
were suppressed in cells transfected with dynamin-mutant K44A
(Dyn-K44A), which is defective in GTPase activity [17,18].
Signaling from GPCR inside the cell is persistent and appears to
trigger specific downstream effects [19]. Visualizing and tracking
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understanding the molecular mechanisms of receptor signaling
[20]. However, the association of a1A-AR endocytic trafficking
and activation of MAPKs is still unknown.
We aimed to investigate whether an endocytic process is
involved in ERK1/2 activation induced by a1A-AR. By real-time
tracking, we found a time-dependent dynamic pattern of a1A-AR
endocytosis with stimulation and the involvement of the
cytoskeleton, especially actin-filaments, in this process. This
relationship was further examined by colocalization of a1A-AR
with reorganized cytoskeletons. We provide evidence for an
involvement of endocytosis in a1A-AR-induced activation of
ERK1/2, which differs from that of a1B-AR via a Gq/PLC/
PKC pathway.
Materials and Methods
Materials
Cytochalasin D, nocodazole, PE and U73122 were from Sigma
(St. Louis, MO). Ro 31–8220, prazosin and phorbol 12-myristate,
13-acetate (PMA) were from Calbiochem (La Jolla, CA). Phospho-
p38 MAPK (Thr180/Tyr182), -p42/44 MAPK (Thr202/Tyr204),
-PKC (pan) (Ser660), and -C-Raf (Ser338) antibodies were from
Cell Signaling Technology (Beverly, Mass). Antibodies against
ERK1/2, PKC (pan), C-Raf, p38, FLAG-tag and HA-tag were
from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish
peroxidase (HRP)-conjugated goat anti-mouse and anti-rabbit
antibodies were from Beijing Zhongshan Golden Bridge Biotech-
nology. Alexa 488-conjugated WGA, Alexa 555 and 633 IgG and
Alexa 488-conjugated phalloidin were from Invitrogen. All other
chemicals were of analytical grade.
Cell culture, plasmids and transfection
HEK-293A cell lines were obtained from Invitrogen. Receptor
constructs and HEK-293A cells stably transfected with a1A-AR or
a1B-AR were described previously [21]. Dyn-K44A was a gift from
Ming Zhao (La Jolla Institute for Molecular Medicine, San Diego,
CA). Amphiphysin I construct was a gift from Pietro De Camilli
(Yale University School of Medicine, New Haven, CT). Trans-
fection involved use of Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions.
Membrane receptor labeling and tracking
FLAG-tagged receptors were labeled with anti-FLAG mono-
clonal antibody (12.5 mg/ml) for 10 min and then Alexa FLourH
555 goat anti-mouse IgG (Invitrogen) (3.75 mg/ml) for 10 min as
described previously [21,22]. Before fluorescence experiments,
cells were washed 3 times in phosphate buffered saline (PBS) buffer
(pH 7.4; 37uC). Live imaging involved use of a wide-field
fluorescence microscope equipped with a 1006/1.40NA Plan
Apochromat objective (Olympus, Japan) and a 14-bit, back-
illuminated, electron-multiplying charge-coupled device camera
(Andor iXon DU-897 BV). The microscope was also equipped
with a cell incubation system (INU-ZIL-F1, TOKAI HIT), which
ensured live-cell imaging at 37uCi n5 %C O 2. Fluorescence was
excited at 532-nm by an argon laser (Melles Griot, Carlsbad, CA).
Movies were acquired at a frame rate of 20 Hz by use of
MetaMorph software (Molecular Devices). Trajectories from cells
observed under the given labeling procedure were plotted and
resolved as described previously [21].
Fluorescence microscopy
After drug treatment, cells were fixed for 15 min in 4%
paraformaldehyde in PBS and permeabilized with 0.2% Triton X-
100. After washes with PBS, cells were incubated for 25 min with
TRITC-labeled phalloidin (Sigma). The samples were viewed
under a laser scanning confocal microscope (TCS SP2, Leica
Microsystems) with a Plan-Apo 636/1.32 oil immersion objective
(Leica Microsystems); images were collected by use of Leica TCS
SP2 v2.611537. The 488- and 532-nm laser beam was focused by
a Leica Apochromat with ,200 lW power irradiation. The
pinhole size was 1 airy unit.
Western blot analysis
Protein expression was examined by western blot analysis as
previously described [23]. Briefly, samples were separated by 10%
SDS-PAGE and transferred to nitrocellulose membranes. After
being blocked, blots were probed with the appropriate primary
antibodies overnight at 4uC or for 2 h at room temperature, then
washed and incubated with HRP-conjugated secondary antibody.
Bands were visualized by use of a super-western sensitivity
chemiluminescence detection system (Pierce). Autoradiographs
were quantitated by densitometry (Science Imaging System, Bio-
Rad).
Results
Tracking a1A-AR stimulated by agonist in single living
cells in real time
We studied the dynamic properties and mechanisms of receptor
transport in HEK-293A cells stably transfected with a FLAG-
tagged a1A-AR construct. a1A-AR was detected on the surface of
living HEK-293A–a1A-AR cells by use of a monoclonal primary
antibody and Alexa-555 IgG (Fig. 1A). After incubation with PE,
an a1-AR agonist, some of the a1A-AR particles trafficked inward
in the cells. From recorded movies, we tracked the trajectories of
trafficking a1A-AR particles. Figure 1B shows 2 sample trajectories
of a1A-AR particles (as marked in Fig. 1A) with directed movement
within 8 sec on PE stimulation. To quantify the velocities of a1A-
AR movements, we plotted the mean square displacement (MSD)
versus time (Fig. 1C), which also showed the directional movement
of these particles.
We then resolved the velocities at different time after PE
stimulation [21]. Figure 1D shows the time-dependent velocity
distribution of endocytic a1A-AR with PE stimulation during
1 hour (10-min intervals). At the early stage of the activation (first
30 min), the receptor mainly moved at a low velocity at a peak of
about 0.3 mm/s. After stimulation for 40 to 60 min, movements
became much faster, with high velocity trajectories increased
gradually. The main peak of the highest velocity was about
0.8 mm/s. Thus, in general, the active movement of a1A-AR
vesicles was slower at the early phase of endocytosis and faster at
the later phase.
Actin filament-mediated endocytosis of a1A-AR
We used confocal microscopy to determine the association of
endocytic receptors with cytoskeleton, actin and microtubules,
respectively. a1A-AR vesicles largely colocalized with F-actin after
20-min PE stimulation (Fig. 2A). With 50-min PE stimulation,
some of the a1A-AR vesicles colocalized with microtubules. With
higher resolution imaging, we observed a more relevant relation
between reorganized actin and a1A-AR; at 20 min after PE
stimulation, small actin patches and tails appeared in the cells
(Fig. 2B). Most of the actin patches showed colocalization of a a1A-
AR vesicle. Actin may use a1A-AR-associated actin patches as
polymerization sites, as was reported for virus internalization [24].
The changes were transient, and after 50-min stimulation, most of
actin patches and tails disappeared. And a1A-AR vesicles became
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endocytic trafficking in the early phase depends on F-actin.
To justify the role of F-actin in regulation of a1A-AR
endocytosis, cytochalasin D was used before PE stimulation to
inhibit the actin polymerization. Incubated for 5 min with 5 mM
cytochalasin D, a1A-AR congregated on membrane even after PE
stimulation (Fig. 2C). It provides further evidence that a1A-AR
endocytosis is regulated by actin filaments.
Receptor endocytosis is required for ERK1/2 activation
induced by a1A-AR
To test whether endocytosis is involved in the a1A-AR induced
signaling, we first examined the activation of ERK1/2 and p38
MAPK with PE stimulation. ERK1/2 and p38 MAPK phosphor-
ylation significantly increased at 10 and 20 min after PE treatment
and then decreased to the basal level (Fig. 3A,B). PE also caused a
secondary increase of p38 MAPK phosphorylation after 50-min
treatment. We then used 4uC incubation to inhibit a1A-AR
endocytosis [25,26]. a1A-AR remained on the membrane after PE
stimulation at 4uC (Fig. 3C). a1A-AR endocytosis was markedly
inhibited at 4uC as compared with at 37uC. 4uC chilling almost
completely abrogated the a1A-AR-induced ERK1/2 activation,
whereas activation of p38 was not modified (Fig. 3D). To ensure
that the ERK1/2 was not defective in phosphorylation at 4uC
incubation, we measured PMA-induced activation of ERK1/2 in
4uC. PMA activated both PKC and ERK1/2 at 4uC and at 37uC
Figure 1. Tracking a1A-AR in response to agonist stimulation. (A) a1A-ARs were detected with anti-FLAG antibody and Alexa-555 IgG in live
HEK-293A–a1A-AR cells at 37uC. Images were captured after 30-min stimulation with 10 mM phenylephrine (PE). Two sample trajectories of a1A-AR
particles are shown with red lines (1 and 2). Bar: 10 mm. (B) The trajectories in (A) were plotted (1 and 2, respectively). (C) The plot of the mean square
displacement (,r
2.) against time (t) to the trajectory in Fig. B(2). The red line is a fit by ,r
2.=4Dt+(vt)
2. Directed movement was confirmed by the
superlinear MSD-Dt plots. (D) Velocities of directional movements of a1A-AR resolved from tracked trajectories at various times after 10 mMP E
stimulation plotted in probability histograms. (n=36, 61, 51, 58, 49 and 53 trajectories in separated cells, respectively).
doi:10.1371/journal.pone.0021520.g001
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a1A-AR at 4uC was not due to a defect in ERK1/2 signaling but
rather to a defect in receptor endocytosis.
To further define the role of endocytosis in a1A-AR induced
signaling, we tested the effect of the mutant Dyn-K44A, used to
induce trafficking defects of receptors in many cells [27,28], on
ERK1/2 and p38 activation. Overexpression of HA-tagged Dyn-
K44A in HEK-293A–a1A-AR cells suppressed the activation of
ERK1/2 but not p38 (Fig. 3F, 3G). Therefore, endocytosis is
required for a1A-AR-induced ERK1/2 but not p38 MAPK
activation.
Actin organization is involved in ERK1/2 activation
induced by a1A-AR
Actin filaments play a pivotal role in a1A-AR trafficking,
especially in the early phase of endocytosis (Fig. 1, 2). Therefore,
we tested the contribution of actin polymerization to a1A-AR-
induced activation of ERK1/2. We pretreated cells with
cytochalasin D or nocodazole before PE stimulation to disrupt
to disrupt organizing actin or microtubules, respectively. In cells
treated for 5 min with 5 mM cytochalasin D, filamentous form of
actin was depolymerized and was replaced by aggregated actin,
with microtubules appearing normal (Fig. 4A). Treatment with
Figure 2. a1A-AR endocytosis is regulated by cytoskeleton. (A) Colocalization of a1A-AR with F-actin and microtubules after agonist
stimulation. Cells were stimulated with 10 mM PE for 20 or 50 min. Untreated cells were used as control. a1A-AR was labeled with anti-FLAG antibodies
and Alexa 555 IgG (red). F-actin was labeled with Alexa 488-conjugated phalloidin (green). Microtubules were labeled with antibodies and Alexa 633
IgG (blue). Last column: 56 magnification of selected boxed regions. Bar: 10 mm. (B) High-resolution imaging of colocalization of a1A-AR with
reorganized actin after stimulation. Cells were treated with agonist for 20 or 50 min, and then labeled with antibodies against a1A-AR and Alexa 488-
conjugated phalloidin against F-actin (red) (bottom row). Bar: 5 mm. (C) Inhibition of a1A-AR endocytosis by Cytochalasin D. HEK-293A–a1A-AR cells
were pre-incubated with cytochalasin-D (Cyto-D; 5 mM, 5 min), then stimulated with 10 mM PE for 20 min. F-actin was stained by Alexa 488-
conjugated Phalloidin (green), a1A-ARs were detected with anti-FLAG antibody and Alexa-555 IgG (red). NS: no stimulation. Bar: 10 mm.
doi:10.1371/journal.pone.0021520.g002
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microtubule but left F-actin intact. These data confirm the specific
effects of cytochalasin D and nocodazole on depolymerizing F-
actin and microtubules, respectively. Treatment with cytochalasin
D impaired the ability of a1A-AR to activate ERK1/2 but that
with nocodazole did not affect the ERK1/2 activation at 20 min
of PE stimulation and even increased the phosphorylation levels of
ERK1/2 at a later stage of stimulation (Fig. 4B). However,
activation of p38 seemed insensitive to the disruption of F-actin or
microbules.
To further justify the role of endocytic trafficking in the ERK1/
2 activation, we overexpressed amphiphysin, found to be critical
Figure 3. Receptor endocytosis is involved in ERK1/2 activation by a1A-AR stimulation. (A) Representative western blot showing activation
of ERK1/2 and p38 after 10-mM PE treatment for the indicated times. (B) Relative ERK1/2 and p38 activeity after PE stimulation are shown. Data are
means6SEM of results obtained in three independent experiments. Statistical significance of the difference was assessed using one-way ANOVA
analysis. *, p,0.05 versus 0 min. (C) Effect of 4uC chilling on agonist-induced a1A-AR endocytosis. Cells were incubated in 4uCo r3 7 uC for 30 min then
stimulated with 10 mM PE for 20 min. a1A-ARs were detected with anti-FLAG antibody and Alexa-555 IgG (red), and plasma membrane was labeled
with Alexa 488-conjugated WGA (green). (D) Western blot analysis of ERK1/2 and p38 phosphorylation with PE stimulation for the indicated times at
4uC. Stimulation at 37uC is a control. (E) Phorbol 12-myristate, 13-acetate (PMA)-induced activation of protein kinase C (PKC) and ERK1/2 at 4uC. Cells
were incubated in 4uCo r3 7 uC for 30 min then stimulated with 0.1 mM PMA for 20 min. (F) Dynamin mutation inhibits the activation of ERK1/2 by a1A-
AR. HEK-293A–a1A-AR cells were cultured and infected with Dyn-K44A or vectors. After 40 h, cells were treated for 20 min with 10 mM PE. Protein
expression of phospho-ERK1/2 and total ERK1/2 and p38 were measured. Expression of Dyn-K44A (HA-tagged) was identified with blotting of HA-tag.
(G) Quantification of relative ERK1/2 activation corresponding to (F) was performed by densitometric analysis. Data are means6SEM of results
obtained in three independent experiments. Statistical significance of the difference was assessed using one-way ANOVA analysis. ***, p,0.001
versus Vector 0 min.
###, p,0.001 versus Vector 20 min.
doi:10.1371/journal.pone.0021520.g003
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Overexpressed amphiphysin increased the phosphorylation level
of ERK1/2 at 20- but not 50-min stimulation (Fig. 4C), which
agrees with results showing that F-actin preferentially mediates the
early-stage but later-stage trafficking of a1A-AR (Fig. 1). These
data identified the association of F-actin in the ERK1/2 activation
with a1A-AR agonist stimulation.
ERK1/2 activation by a1A-AR is independent of the
Gq/PLC/PKC pathway
One of the earliest events in the signaling cascade initiated by
a1A-AR is Gq-mediated activation of PLC, with a resulting
increase in PKC phosphorylation [14]. To test whether the Gq/
PLC/PKC pathway is involved in the a1A-AR-induced activation
of ERK1/2, we examined the phosphorylation level of PKC and
its downstream C-Raf molecule by a1A-AR with 4uC incubation or
cytochalasin-D treatment. As compared with 37uC, 4uC incuba-
tion had no effect on the a1A-AR-activation of PKC or C-Raf, but
it inhibited the activation of ERK1/2 (Fig. 5A). Similarly,
pretreatment with cytochalasin-D before PE did not impair a1A-
AR-induced PKC and C-Raf activation (Fig. 5B). Thus, a1A-AR
endocytosis was not involved in the Gq/PLC/PKC pathway.
To detemine the role of Gq/PLC/PKC signaling pathway in
a1A-AR-induced ERK1/2 activation, HEK-293A–a1A-AR cells
were treated with U73122 before PE exposure (Fig. 6A). U73122
is a pharmacological agent commonly used to demonstrate a role
of Gq activation of PLC, which inhibits the PLC-dependent
process [30]. U73122 suppressed PKC phosphorylation but did
not alter the activation of ERK1/2 with PE stimulation. To
compare the role of Gq/PLC/PKC signaling in the activation of
ERK1/2 by a1A-AR and a1B-AR, we also examined the effect of
U73122 in HEK-293A cells stably transfected with a1B-AR.
U73122 inhibited both PKC phosphorylation and ERK1/2
activation in HEK-293A–a1B-AR cells with PE stimulation
(Fig. 6B). The PKC inhibitor Ro 31–8220 used before PE
stimulation showed inhibition of PKC but not ERK1/2 activation
with a1A-AR induction (Fig. 6C), and inhibition of both PKC and
ERK1/2 with a1B-AR induction (Fig. 6D). The effects of U73122
and Ro 31–8220 on HEK-293A–a1A-AR or –a1B-AR cells suggest
that the Gq/PLC/PKC pathway is required for ERK1/2
activation induced by a1B-AR but not a1A-AR.
Discussion
GPCRs activate MAPKS through distinct pathways in cells, and
endosomal signaling has an important role in receptor signal
transduction. We investigated the involvement of endocytosis in
a1A-AR-induced activation of ERK1/2 in HEK-293A cells.
Agonist-mediated endocytic trafficking of a1A-AR was assessed
by real-time imaging of living, stably transfected cells. a1A-AR was
internalized dynamically in cells with agonist stimulation, and
actin filaments regulated the initial trafficking of a1A-AR. a1A-AR-
induced activation of ERK1/2 but not p38 MAPK was sensitive to
disruption of endocytosis. a1A-AR-induced activation of PKC and
C-Raf by was not affected by endocytosis disruption. Thus, the
endocytic pathway is involved in a1A-AR-induced ERK1/2
activation and is independent of Gq/PLC/PKC signaling.
Real-time microscopy with high-tempo resolution has novel
implications in the investigation of the behavior of receptors. For
single particle tracking in this study, a1A-AR was detected on the
surface of living HEK-293A–a1A-AR cells by use of a monoclonal
primary antibody and Alexa-555 IgG. It should be aware of the
potential effects of this labeling method on receptor trafficking and
signaling. We found that the labeling with antibodies did not
impair the calcium response of a1A-AR among the labeled cells, as
compared with non-labeled ones [31]. And it did not affect the
ERK1/2 signaling (See Supporting Information Figure S1).
Previously, we showed a1A-AR transport with an average step
size of 33 nm [21]. In the present work, a1A-AR showed a spatial
and time-dependent trafficking pattern with PE stimulation. Near
the plasma membrane, the a1A-AR particles were transported a
relatively short distance (as shown in Fig. 1A and 1B, trajectory 1)
within 8 sec. Inside the cells, the a1A-AR particles moved farther
(as shown in Fig.1A and 1B, trajectory 2) in the same time interval.
Long-distance transportation allows a1A-AR-containing vesicles to
reach late endosomes or lysosomes, which were mostly located
Figure 4. Actin organization is involved in ERK1/2 activation
induced by a1A-AR. (A) Effect of actin and microtubule-disrupting
drugs on cytoskeleton organization after agonist stimulation. HEK-
293A–a1A-AR cells were pre-incubated with cytochalasin-D (Cyto-D;
5 mM, 5 min) or nocodazole (noc; 20 mM, 20 min) at 37uC, then
stimulated with 10 mM PE for 20 min. F-actin was stained by TRITC-
conjugated Phalloidin (red), and microtubules were stained with anti-a-
tubulin antibody and Alexa-488 IgG (green). Nuclei were stained with
Hochest-33342 (blue). Bar: 10 mm. (B) Effect of cytoskeleton disrupton
on the activation of ERK1/2 and p38 after a1A-AR stimulation. HEK-
293A–a1A-AR cells were pre-incubated with Cyto-D (5 mM, 5 min) or
nocodazole (20 mM, 20 min) in 37uC, then treated with 10 mM PE for 20
and 50 min. Cell lysates were immunoblotted for the phosphrylation of
ERK1/2 and p38. (C) Overexpression of amphiphysin enhanced the
activation of ERK1/2 after agonist stimulation. HEK-293A–a1A-AR cells
were transfected with amphiphysin plasmid, then treated with 10 mM
PE for 20 and 50 min. Cell lysates were immunoblotted for analysis of
phospho and total ERK1/2.
doi:10.1371/journal.pone.0021520.g004
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21520Figure 5. PKC and C-Raf activation with a1A-AR stimulation is not impaired by 46C chilling or F-actin disruption. (A) HEK-293A–a1A-AR
cells were pre-incubated at 4uCo r3 7 uC for 30 min, then stimulated with 10 mM PE for 20 min. PKC, C-Raf and ERK1/2 activity was measured by
western blot analysis. (B) HEK-293A–a1A-AR cells were pre-incubated with or without 5 mM cyto-D for 5 min, then stimulated with 10 mM PE for
20 min. PKC, C-Raf and ERK1/2 activity was measured by western blot analysis.
doi:10.1371/journal.pone.0021520.g005
Figure 6. ERK1/2 activation by a1A-AR is independent of Gq/PLC/PKC pathway. (A, B) Inhibition of phospholipase C (PLC) by U73122
affected ERK1/2 activation by a1B-AR but not a1A-AR. HEK-293A–a1A-AR or –a1B-AR cells were pre-incubated with 1 mM U73122 or prazosin or not for
30 min. Then cells were treated with 10 mM PE for 20 min. PKC and ERK1/2 activity was measured by western blot analysis. (C, D) Inhibition of PKC by
Ro 31–8220 affected ERK1/2 activation by a1B-AR but not a1A-AR. HEK-293A–a1A-AR or –a1B-AR cells were pre-incubated with 1 mM Ro 31–8220 or
prazosin or not for 30 min, then were treated with 10 mM PE for 20 min. PKC and ERK1/2 activity were measured by western blot analysis.
doi:10.1371/journal.pone.0021520.g006
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mainly moved at a slow velocity, at a peak of about 0.3 mm/sec,
which is consistent with the velocity of a single myosin motor
walking along actin in vitro [32,33]. After 40- to 60-min
stimulation, the main peak of the higher velocity was about
0.8 mm/sec, which is similar to the value reported for movement
along microtubules under in vitro conditions [34,35]. Thus, the
movement of a1A-AR vesicles mainly depends on actin at the early
phase of endocytosis and on microtubules at the later phase.
Confocal microscopy further verified that endocytic traffic of a1A-
AR was mediated by reorganized actin (Fig. 2A, 2B).
Disruption of endocytosis by 4uC chilling, dynamin mutation
and F-actin depolymerizing all indicated that the endocytic
process was associated in a1A-AR-induced activation of ERK1/
2. Many studies have implied a critical role for the ERK1/2
signaling pathway in cardiac myocytes [9–11]. Recently, a1A-AR
was shown to signal through ERK1/2 to promote cardiac
hypertrophy [36] or survival signals [12]. a1A-AR but not a1B-
AR rescued a1ABKO cardiac myocytes from cell death, and only
a1A-AR could mediate ERK1/2 activation in the myocytes [12].
Activation of phosphoinositide-3-kinase (PI3K) and Ras protein
induces activation of a series of growth or proliferation-related
protein kinase cascades [37]. Investigation of the role of PI3K and
Ras in the activation of ERK1/2 by 2 a1-ARs in NIH3T3 cells
revealed that overexpression of a dominant-negative Ras mutant
attenuated the a1B-AR– but not a1A-AR-mediated activation of
ERK1/2. And overexpression of a dominant-negative PI3K
mutant (p85 subunit) attenuated a1A-AR- but not a1B-AR-induced
ERK1/2 activation [38]. Therefore, a1A-AR and a1B-AR
differentially activate downstream effectors, which further under-
scores the complexity of a1-AR signaling pathways. We found
endocytic trafficking involved in a1A-AR induced ERK1/2
activation and that it was independent of Gq/PLC/PKC signaling.
By contrast, a1B-AR-induced ERK1/2 activation required Gq/
PLC/PKC signaling, as was previously reported [39]. Thus, a1A-
AR uses pathways different from those of a1B-AR to activate
ERK1/2.
A number of studies have found a non-Gq-protein signaling
pathway in a1A-AR function. An a1A-AR mutant defective in Gq
coupling could also activate calcium influx when coactivated with
b2-AR [16]. Thus, the functional interaction of these 2 receptors
involves heterodimer formation and/or the presence of uniden-
tified non-Gq signaling events in response to a1A-AR stimulation.
Activation of calcium influx and PKC may be key events coupling
Gq- and Gi-coupled receptor activation to MAPK activation [40].
Berts et al. showed that the Ca
2+ chelator BAPTA dose-
dependently abolished norepinephrine (NE) -stimulated Ca
2+
responses but not ERK1/2 activation. The potent PKC inhibitor
bisindolylmaleimide I dose dependently inhibited ERK1/2
activation by phorbol ester tumor-promoting agent but not NE.
Thus, Ca
2+ release and PKC activation are neither necessary nor
sufficient for a1A-AR-mediated activation of ERK1/2 in PC12
cells stably transfected with a1A-AR [41]. Therefore, ERK1/2
activation induced by a1A-AR may be independent of traditional
Gq-coupled second-messenger pathways. We found that a1A-AR-
induced ERK1/2 activation was unaffected by the PLC inhibitor
U73122 and PKC inhibitor R0 31–822, which further identifies a
non-Gq signaling pathway involved in a1A-AR-mediated ERK1/2
activation.
Arrestins are critically important for desensitization, endocyto-
sis, and G protein-independent signaling of GPCRs [42]. One of
the early evidences that b-arrestins are active participants in
signaling was the observation that dominant-negative mutants of
b-arrestins inhibited b2-AR-induced activation of ERK1/2 [18].
b-arrestins similarly participate in ERK1/2 signaling by other
GPCRs, including neurokinin-1 receptor, protease activated
receptor 2, angiotensin II type 1A receptor, and vasopressin V2
receptor [43–46]. The stability of receptor–b-arrestin complex
controlled the mechanism and extent of ERK1/2 activation [44].
However, results from both coimmunoprecipitation experiments
and b-arrestin translocation assays indicated that the agonist-
induced interaction of a1A-AR with b-arrestins was much weaker
than that of a1B-AR. In addition, a1A-AR did not bind AP50, a
subunit of the clathrin adaptor complex AP2. Moreover
epinephrine-induced increase of the association of the a1A-AR
and b-arrestin 1 or 2 was not statistically significant [47]. Thus,
defining the role of b-arrestins in the endocytosis of a1A-AR and
a1A-AR-induced ERK1/2 activation is important. PI3K has a
potential role in the a1A-AR induced ERK1/2 activation [38] and
has been found to regulate intracellular vesicular transport at
multiple steps [48,49]. PI3K may be involved in a1A-AR mediated
ERK1/2 activation through an endocytosis pathway but remains
to be elucidated.
In summary, we identified a putative role of endocytosis in the
regulation of the MAPK pathway under a1A-AR stimulation in
cells. Through analysis of receptor tracking in live cells and
confocal microscopy, we conclude that the a1A-AR endocytic
process is actin-related. Endocytosis and actin reorganization are
involved in a1A-AR induced activation of ERK1/2 but not p38,
and Gq/PLC/PKC signaling is not required in this process. Thus,
we reveal a novel pathway of ERK1/2 activation in a1-AR
subtypes. We provide the first biological evidence for a role of
endocytosis in the signaling of the a1-AR family, which challenges
the classical view that a1A-AR act through Gq/PLC/PKC
signaling. Moreover, the mechanism by which a1A-AR induces
ERK1/2 activation differs from that of a1B-AR. We provide a
possible molecular explanation for the difference between a1A-AR
and a1B-AR in activation of ERK1/2 in cardiac myocytes.
Because receptor vesicles could link to various intracellular
membrane compartments in the endocytic process, the distinct
spatiotemporal profile of ERK1/2 activation induced by a1A-AR
has profound implications in a1A-AR-mediated survival signaling
in cardiac myocytes. In-depth studies of this signaling pathway
should add great potential for developing more efficacious and/or
safer treatment of heart failure and other clinical conditions.
Supporting Information
Figure S1 Labeling with antibodies did not impair the ERK1/2
signaling induced by a1A-AR stimulation. HEK-293A–a1A-AR
cells were pre-incubated with or without anti-FLAG antibody and
Alexa-555 IgG. After phenylephrine (PE) treatment, the phos-
phorylation level of ERK1/2 did not show significant difference
among labeled and unlabeled cells. Prazosin (Pra, antagonist of
a1A-AR) inhibited the PE-induced ERK1/2 activation in both.
(TIF)
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